Donanemab slowed cognitive and functional decline of patients with mild Alzheimer’s by 32% compared with placebo Link to press release: https://www.prnewswire.

Donanemab slowed cognitive and functional decline of patients with mild Alzheimer’s by 32% compared with placebo Link to press release: https://www.prnewswire.com/news-releases/lillys-donanemab-slows-clinical-decline-of-alzheimers-disease-in-positive-phase-2-trial-301204830.html https://www.prnewswire.com/news-releases/lillys-donanemab-sl...